相似文献
1
[Intermediate-high dose cytarabine consolidation therapy in younger adults with acute myeloid leukemia and favorable-intermediate cytogenetic risk: a retrospective study of 124 patients in a single Chinese hospital].
Zhonghua Xue Ye Xue Za Zhi. 2019 May 14;40(5):429-431. doi: 10.3760/cma.j.issn.0253-2727.2019.05.016.
2
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.
3
High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):438-43. doi: 10.1016/j.clml.2012.05.007. Epub 2012 Sep 25.
4
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.
5
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4611-4621. doi: 10.1007/s00432-022-04356-9. Epub 2022 Sep 28.
6
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22.
7
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
Eur J Haematol. 2023 Dec;111(6):888-894. doi: 10.1111/ejh.14094. Epub 2023 Aug 28.
8
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.
9
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851.
10
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29.
引用本文的文献
1
The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
Ann Transl Med. 2022 Aug;10(16):858. doi: 10.21037/atm-22-2965.
2
Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
Medicine (Baltimore). 2021 Jan 22;100(3):e24273. doi: 10.1097/MD.0000000000024273.
本文引用的文献
1
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24.
2
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.
3
High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Curr Hematol Malig Rep. 2013 Jun;8(2):141-8. doi: 10.1007/s11899-013-0156-3.
4
Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Am J Hematol. 2013 Jun;88(6):533-4. doi: 10.1002/ajh.23440. Epub 2013 May 2.
5
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851.
6
[Role of high-dose cytarabine as consolidation therapy for cytogenetically intermediate AML: a single center analysis].
Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):229-32.
7
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
J Clin Oncol. 2011 Jul 1;29(19):2696-702. doi: 10.1200/JCO.2010.33.7303. Epub 2011 May 23.
8
Cytarabine dose for acute myeloid leukemia.
N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.
9
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Blood. 2011 Feb 24;117(8):2366-72. doi: 10.1182/blood-2010-07-295279. Epub 2010 Dec 29.
10
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.
Zotero 插件